KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q3 2025 value amounting to $1.9 billion.

  • CRISPR Therapeutics AG's Cash & Current Investments fell 102.99% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year decrease of 102.99%. This contributed to the annual value of $1.9 billion for FY2024, which is 1240.53% up from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Cash & Current Investments of $1.9 billion as of Q3 2025, which was down 102.99% from $1.7 billion recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Cash & Current Investments ranged from a high of $2.6 billion in Q2 2021 and a low of $1.7 billion during Q4 2023
  • Over the past 5 years, CRISPR Therapeutics AG's median Cash & Current Investments value was $1.9 billion (recorded in 2024), while the average stood at $2.0 billion.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first soared by 17399.57% in 2021, then crashed by 2369.82% in 2022.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Cash & Current Investments stood at $2.4 billion in 2021, then decreased by 23.7% to $1.8 billion in 2022, then fell by 6.7% to $1.7 billion in 2023, then grew by 12.41% to $1.9 billion in 2024, then rose by 0.62% to $1.9 billion in 2025.
  • Its last three reported values are $1.9 billion in Q3 2025, $1.7 billion for Q2 2025, and $1.9 billion during Q1 2025.